VYNE Therapeutics Inc.

NasdaqCM:VYNE Stock Report

Market Cap: US$21.9m

VYNE Therapeutics Management

Management criteria checks 2/4

VYNE Therapeutics' CEO is Dave Domzalski, appointed in Mar 2020, has a tenure of 6.25 years. total yearly compensation is $2.33M, comprised of 27.4% salary and 72.6% bonuses, including company stock and options. directly owns 1.32% of the company’s shares, worth $289.02K. The average tenure of the management team and the board of directors is 6.3 years and 5.2 years respectively.

Key information

Dave Domzalski

Chief executive officer

US$2.3m

Total compensation

CEO salary percentage27.36%
CEO tenure6.3yrs
CEO ownership1.3%
Management average tenure6.3yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

Analysis Article • Jun 27

We're A Little Worried About VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 09

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Apr 27

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 04

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 12

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

VYNE Therapeutics press release (NASDAQ:VYNE): Q2 Non-GAAP EPS of -$0.13 beats by $0.02. Revenue of $0.13M (-55.2% Y/Y) beats by $0.03M. As of June 30, 2022, VYNE had cash and cash equivalents of $42.8 million. Shares -4% PM.
Analysis Article • Jul 02

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Mar 19

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 13

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Sales of Vyne Therapeutic's minocycline products were just $4 million last quarter which may hamper the company’s ability to sell or license the franchise. Vyne has shifted its focus from marketing the approved minocycline products to 3 pre-clinical assets which require substantial cash and expose investors to a high degree of clinical risk. The largest institutional shareholder has sold most of their position. The cash position is sufficient only through Q2 of 2022 and significant dilution is likely.
Analysis Article • Dec 03

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Aug 13

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Market forces rained on the parade of VYNE Therapeutics Inc. ( NASDAQ:VYNE ) shareholders today, when the analysts...
Seeking Alpha • Jun 30

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

VYNE stock has depreciated by 65% in the last 3 months. There are no overwhelmingly critical factors behind this. The market, and smart money, just seem to dislike the stock.

CEO Compensation Analysis

How has Dave Domzalski's remuneration changed compared to VYNE Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$22m

Dec 31 2025US$2mUS$638k

-US$27m

Sep 30 2025n/an/a

-US$34m

Jun 30 2025n/an/a

-US$39m

Mar 31 2025n/an/a

-US$42m

Dec 31 2024US$2mUS$638k

-US$40m

Sep 30 2024n/an/a

-US$34m

Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$29m

Dec 31 2023US$3mUS$638k

-US$28m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$1mUS$638k

-US$34m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$40m

Mar 31 2022n/an/a

-US$42m

Dec 31 2021US$5mUS$638k

-US$44m

Sep 30 2021n/an/a

-US$59m

Jun 30 2021n/an/a

-US$69m

Mar 31 2021n/an/a

-US$226m

Dec 31 2020US$3mUS$501k

-US$256m

Compensation vs Market: Dave's total compensation ($USD2.33M) is above average for companies of similar size in the US market ($USD647.55K).

Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.

CEO

Dave Domzalski (59 yo)

6.3yrs
Tenure
US$2,330,560
Compensation

Mr. David T. Domzalski, also known as Dave, has been President, Chief Executive Officer and Director at VYNE Therapeutics Inc. (formerly known as Menlo Therapeutics Inc.). since March 9, 2020. Mr. Domzalsk...

Leadership Team

NamePositionTenureCompensationOwnership
David Domzalski
CEO, President & Director6.3yrsUS$2.33m1.32%
$ 289.0k
Iain Stuart
Chief Scientific Officer6.3yrsUS$1.01m0.19%
$ 41.4k
Mutya Harsch
General Counsel6.3yrsUS$1.00m0.17%
$ 36.6k
Tyler Zeronda
CFO & Treasurer5yrsno data0.30%
$ 65.7k
Darrell Rigel
Consultant7.6yrsUS$115.20kno data
6.3yrs
Average Tenure
53yo
Average Age

Experienced Management: VYNE's management team is seasoned and experienced (6.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Domzalski
CEO, President & Director6.3yrsUS$2.33m1.32%
$ 289.0k
Sharon Surrey-Barbari
Independent Non Employee Director6.3yrsUS$74.46k0.0031%
$ 684.8
Patrick LePore
Lead Independent Director5.8yrsUS$76.96k0.15%
$ 33.9k
Steven Basta
Director10.8yrsUS$56.20k0%
$ 0
Elisabeth Sandoval-Little
Independent Director7.3yrsUS$71.20k0%
$ 0
Roy Fleischmann
Member of Scientific Advisory Board4.7yrsno datano data
Martin Okun
Member of Scientific Advisory Board4.7yrsno datano data
David Sachar
Member of Scientific Advisory Board4.7yrsno datano data
Olaf Stuve
Member of Scientific Advisory Board4.7yrsno datano data
Johnathan Whetstine
Member of Scientific Advisory Board4.7yrsno datano data
5.2yrs
Average Tenure
64yo
Average Age

Experienced Board: VYNE's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 18:35
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

VYNE Therapeutics Inc. is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas TsaoBarclays
Jason Matthew GerberryBofA Global Research
Louise ChenGuggenheim Securities, LLC